Aurobindo Pharma · NSE: AUROPHARMA · BSE: 524804

Q2 FY25 results · Jul–Sep 2024

Aurobindo Pharma reported revenue from operations of ₹7,796.07 crore (up 8.0% from Q2 FY24) and net profit of ₹816.95 crore (up 8.6% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY25	Q2 FY24	YoY	Q1 FY25	QoQ
Revenue from operations	7,796.07	7,219.42	+8.0%	7,567.02	+3.0%
Other income	136.00	186.98	−27.3%	220.93	−38.4%
Total income	7,932.07	7,406.40	+7.1%	7,787.95	+1.9%
Profit before share of associates & JVs and tax	1,207.16	1,074.74	+12.3%	1,325.28	−8.9%
Share of profit/(loss) of associates & JVs	0.30	0.90		(1.39)
Net profit for the period	816.95	751.94	+8.6%	918.22	−11.0%
Attributable to shareholders of the company	817.38	757.18	+8.0%	919.22	−11.1%
EPS, basic (₹)	14.00	12.83	+9.1%	15.69	−10.8%
Net margin (%)	10.5	10.4		12.1

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY25	Q2 FY24	YoY	Q1 FY25	QoQ
Revenue from operations	2,824.59	2,668.76	+5.8%	2,460.09	+14.8%
Other income	122.66	67.08	+82.9%	65.32	+87.8%
Total income	2,947.25	2,735.84	+7.7%	2,525.41	+16.7%
Profit before tax	723.75	509.78	+42.0%	446.24	+62.2%
Net profit for the period	537.53	415.74	+29.3%	329.04	+63.4%
EPS, basic (₹)	9.21	7.10	+29.7%	5.62	+63.9%
Net margin (%)	19.0	15.6		13.4

Consolidated

Filed with BSE: 09 Nov 2024, 21:04 IST
Board meeting: 09 Nov 2024
Period: 01 Jul 2024 to 30 Sep 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 09 Nov 2024, 21:04 IST
Board meeting: 09 Nov 2024
Period: 01 Jul 2024 to 30 Sep 2024
Review status: Unaudited
Source: XBRL filing on BSE